Catarina Silva,  —

Neuropore Therapies was awarded a $500,000 grant from The ALS Association to advance in preclinical work its neural protective candidate, NPT1220-312, as a potential treatment of amyotrophic lateral sclerosis (ALS). The company is aiming to bring its molecule into clinical testing late next year. NPT1220-312 is a…

Bloom Science and Duke University have entered into an exclusive licensing agreement that provides the biopharmaceutical company access to the intellectual property and technology related to unique strain isolates and genetic variants of Akkermansia genus bacteria. This type of bacteria has been demonstrated to slow disease progression…

AI Therapeutics‘ lymphoma candidate LAM-002 was identified by the company’s artificial intelligence-based platform — called Guardian Angel — as a possible treatment for amyotrophic lateral sclerosis (ALS). Researchers from AI have already tested and confirmed LAM-002’s therapeutic potential in an ALS context. Now, an independent…

Stealth BioTherapeutics announced the initiation of a Phase 1 trial to assess the safety and tolerability of its investigational oral treatment, SBT-272, in healthy volunteers. SBT-272 is being developed to treat neurodegenerative diseases marked by problems in the workings of mitochondria (a cell’s powerhouse), including amyotrophic lateral sclerosis…

A first patient has been dosed in a Phase 2 trial testing a nanomedicine called CNM-Au8 as a potentially disease-modifying therapy for people with amyotrophic lateral sclerosis (ALS). This safety and efficacy study, due to finish in April 2021, is also completely enrolled, Clene Nanomedicine, the treatment’s developer, announced…

A recently completed Phase 1 trial studying NPT520-34 — an investigational small molecule being developed by Neuropore Therapies for the treatment of Parkinson’s disease and amyotrophic lateral sclerosis (ALS) — has shown the candidate to be safe and well-tolerated in a group of healthy volunteers. The…

A compound found in rice bran oil may lower oxidative stress levels and may be beneficial to people with amyotrophic lateral sclerosis, an early study in fruit flies and disease-related cell models shows. These findings were reported in the study “γ-Oryzanol mitigates oxidative stress and prevents mutant SOD1-Related neurotoxicity…

The most common genetic cause of amyotrophic lateral sclerosis (ALS) disrupts the shape and workings of a compartment inside a cell’s nucleus, researchers report, detailing a discovery that helps to explain how this mutation prompts cell death in ALS. Abnormalities resulting from this mutation, specifically the length of the…

People with mutations in the gene coding for tumor protein p73 (TP73) are at higher risk of developing amyotrophic lateral sclerosis (ALS), researchers report. Their study, “Loss of TP73 function contributes to amyotrophic lateral sclerosis pathogenesis,” was published online in bioRxiv. There’s no doubt that some genes…

High LDL cholesterol levels, also known as “bad cholesterol,” may contribute to the development of amyotrophic lateral sclerosis (ALS), researchers report. Their study, “Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis” was published in Annals of Neurology. Several lifestyle and other factors are thought to…